

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for September 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sandoz Canada Inc.	Cefazolin for Injection USP	Cefazolin for Injection	CEFAZOLIN SODIUM	500 mg/vial	powder for solution, (intramuscular, intravenous)	02308932
Sandoz Canada Inc.	Cefazolin for Injection USP	Cefazolin for Injection	CEFAZOLIN SODIUM	1 g/vial	powder for solution, (intramuscular, intravenous)	02308959
Sandoz Canada Inc.	Cefazolin for Injection USP	Cefazolin for Injection	CEFAZOLIN SODIUM	10 g/vial	powder for solution, (intravenous)	02308967
Apotex Inc	Apo-Azelastine/ Fluticasone	Dymista	AZELASTINE HYDROCHLORIDE, FLUTICASONE	137 mcg/act and 50 mcg/act	nasal suspension spray, metered dose	02540886
Nora Pharma	NRA-Metformin	Glucophage	METFORMIN HCl	850 mg	tablet	02536447
Taro Pharmaceuticals Inc.	Taro-Desvenlafaxine	Pristiq	DESVENLAFAXINE	50 mg	tablet	02532158

Taro Pharmaceuticals Inc.	Taro- Desvenlafaxine	Pristiq	DESVENLAFAXINE	100 mg	tablet	02532166
---------------------------------	-------------------------	---------	----------------	--------	--------	----------